.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
US Army
Johnson and Johnson
Mallinckrodt
Farmers Insurance
Cerilliant
McKesson
Baxter
Accenture
Dow

Generated: September 19, 2017

DrugPatentWatch Database Preview

Endo Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?

ENDO PHARMS INC has five approved drugs.

There are fourteen US patents protecting ENDO PHARMS INC drugs on ENDO PHARMS INC drugs in the past three years.

There are two hundred and thirty-four patent family members on ENDO PHARMS INC drugs in forty-one countries.

Summary for Applicant: Endo Pharms Inc

Patents:14
Tradenames:5
Ingredients:5
NDAs:5
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms Inc
AVEED
testosterone undecanoate
INJECTABLE;INTRAMUSCULAR022219-001Mar 5, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005ABRXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
NASCOBAL
cyanocobalamin
SPRAY, METERED;NASAL021642-001Jan 31, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
COLY-MYCIN S
colistin sulfate; hydrocortisone acetate; neomycin sulfate; thonzonium bromide
SUSPENSION/DROPS;OTIC050356-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe
Endo Pharms Inc
NASCOBAL
cyanocobalamin
SPRAY, METERED;NASAL021642-001Jan 31, 2005RXYesYes► Subscribe► Subscribe ► Subscribe
Endo Pharms Inc
AVEED
testosterone undecanoate
INJECTABLE;INTRAMUSCULAR022219-001Mar 5, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Endo Pharms Inc
NASCOBAL
cyanocobalamin
SPRAY, METERED;NASAL021642-001Jan 31, 2005RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Endo Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms Inc
MEGACE ES
megestrol acetate
SUSPENSION;ORAL021778-001Jul 5, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ENDO PHARMS INC drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalamin
Nasal Spray500 mcg/spray
NASCOBAL
4/28/2017
testosterone undecanoate
Injection250 mg/mL
AVEED
6/11/2014

Non-Orange Book Patents for Endo Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,459,283Nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
8,124,057Propellant-based nanoparticulate dry powder aerosols and method of making► Subscribe
7,521,068Dry powder aerosols of nanoparticulate drugs► Subscribe
7,931,917Nanoparticulate fibrate formulations► Subscribe
6,316,029 Rapidly disintegrating solid oral dosage form► Subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
8,652,464Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
8,236,352Glipizide compositions► Subscribe
8,309,136In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
6,811,767 Liquid droplet aerosols of nanoparticulate drugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Endo Pharms Inc Drugs

Country Document Number Estimated Expiration
New Zealand537324► Subscribe
Canada2386782► Subscribe
Uruguay28231► Subscribe
Eurasian Patent Organization200800099► Subscribe
Austria493971► Subscribe
Japan2010018604► Subscribe
Taiwan200511997► Subscribe
Canada2408848► Subscribe
Australia2003230692► Subscribe
Japan2005536512► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Endo Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00071Netherlands► SubscribePRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
02/028Ireland► SubscribePRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Cerilliant
Baxter
Moodys
Fish and Richardson
Federal Trade Commission
UBS
Medtronic
Cipla
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot